Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

74.48 USD -0.33 (-0.43%)
Streaming Delayed Price Updated: 10:08 AM EDT, Jun 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 140,593
Open 73.90
Bid (Size) 74.48 (1)
Ask (Size) 74.74 (2)
Prev. Close 74.81
Today's Range 73.66 - 74.91
52wk Range 22.36 - 93.94
Shares Outstanding 121,192,210
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join... 
From PR Newswire
Senda Biosciences Announces Closing of $98 Million Series B Financing
Funding to accelerate development of its platform and therapeutic programs 
From PR Newswire

Performance

YTD
+5.12%
+5.12%
1 Month
+34.18%
+34.18%
3 Month
+25.18%
+25.18%
6 Month
-9.70%
-9.70%
1 Year
+184.95%
+184.95%

More News

Read More
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
From PR Newswire
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
From PR Newswire
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
From GlobeNewswire News Releases
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
From GlobeNewswire News Releases
Tuesday Talk: Action!
Tags Cryptocurrencies Financial Commodities
From Blogs - TalkMarkets
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
From Business Wire News Releases
Denali Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating
From Investor's Business Daily
Denali Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
From Investor's Business Daily
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Tags BIIB Parkinson’s Disease General
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.